Price alert —
Sign in to get a one-time email the moment LFCR crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · LFCR
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.0B | $-0.0B | $0.0B | -64.6% | -20.1% |
| 2025-09-30 | $0.0B | $-0.0B | $-0.0B | $0.0B | -32.1% | -9.9% |
| 2025-05-31 | $0.0B | $-0.0B | $0.0B | $0.0B | -3.1% | 8.0% |
| 2025-02-28 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -42.0% | -6.2% |
| 2024-11-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -20.2% | -6.0% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare LFCR vs peers
Line LFCR up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with LFCR
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-06 | -0.43 | -0.30 | -44.9% | -3.8% |
| 2026-03-16 | -0.16 | -0.16 | — | -0.2% |
| 2025-04-03 | -0.47 | -0.15 | -213.3% | -22.3% |
| 2025-01-02 | -0.20 | -0.30 | +34.1% | +14.4% |
| 2024-10-04 | -0.37 | -0.46 | +19.5% | -5.4% |
| 2024-08-26 | -0.20 | 0.16 | -225.0% | -25.2% |
| 2024-08-09 | -0.05 | 0.13 | -135.1% | +8.4% |
| 2024-08-09 | -0.07 | 0.07 | -197.4% | +8.4% |
| 2024-08-09 | -0.31 | -0.13 | -140.6% | +8.4% |
| 2023-08-31 | -0.11 | -0.07 | -50.7% | -1.6% |
| 2023-06-01 | -0.51 | -0.18 | -183.3% | -1.2% |
| 2023-03-16 | -0.42 | -0.11 | -265.2% | -67.3% |
| 2022-10-06 | -0.32 | -0.17 | -90.1% | -5.4% |
| 2022-08-10 | -0.01 | -0.01 | +25.0% | +2.6% |
| 2022-04-05 | -0.08 | -0.03 | -166.7% | -6.0% |
| 2022-01-05 | -0.22 | -0.09 | -149.5% | +1.0% |
| 2021-09-29 | -0.23 | -0.12 | -98.3% | -10.3% |
| 2021-07-28 | -0.10 | -0.02 | -525.0% | -9.1% |
| 2021-04-07 | -0.19 | — | -9400.0% | — |
| 2021-01-06 | 0.02 | 0.03 | -20.0% | — |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| LFCR ★ | $0B | — | -5.8 | 1.4 | 43.0 | -6.2 | 31.4% | — | — | — |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 56.21%
| Holder | Shares | % out |
|---|---|---|
| WYNNEFIELD CAPITAL INC | 4,703,216 | 12.54% |
| Legion Partners Asset Management, LL | 4,461,823 | 11.90% |
| Greenhaven Road Investment Managemen | 3,537,573 | 9.43% |
| 325 Capital Llc | 2,162,466 | 5.77% |
| Blackrock Inc. | 1,877,305 | 5.00% |
| Vanguard Capital Management LLC | 1,290,136 | 3.44% |
| Grizzlyrock Capital, LLC | 827,488 | 2.21% |
| Geode Capital Management, LLC | 815,107 | 2.17% |
| Morgan Stanley | 764,734 | 2.04% |
| State Street Corporation | 642,006 | 1.71% |
Insider activity · 90d
8 buys / 0 sells · ratio 8.0 · Finnhub
- Legion Partners, L.P. I BUY 103,482
- Johnson Paul Harold BUY 69,967
- Antunes Humberto Calheiros BUY 72,967
- Korenberg Matthew E BUY 69,967
- Aryeh Jason BUY 69,967
- Schechter Joshua BUY 133,080
- HOUDE LOVAS KATRINA BUY 135,319
- OBUS NELSON BUY 164,100
- Josephs Paul F 592,915 @ $4.57
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-02 | 8-K | view · |
| 4 | 2026-06-08 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 8-K | 2026-06-05 | 8-K | view · |
| 4 | 2026-05-21 | FORM 4 | view · |
| 10-Q | 2026-05-06 | 10-Q | view · |
| 8-K | 2026-05-06 | 8-K | view · |
| DEF 14A | 2026-04-24 | DEF 14A | view · |
| 4 | 2026-04-16 | FORM 4 | view · |
| 8-K | 2026-03-16 | 8-K | view · |
| 8-K | 2026-03-05 | 8-K | view · |
| 4 | 2026-03-02 | FORM 4 | view · |
| 8-K | 2026-01-16 | 8-K | view · |
| 8-K | 2025-11-17 | 8-K | view · |
| 10-Q | 2025-11-06 | 10-Q | view · |
| 8-K | 2025-11-06 | 8-K | view · |
| 8-K | 2025-10-31 | 8-K | view · |
| 8-K | 2025-09-26 | 8-K | view · |
| DEF 14A | 2025-09-18 | DEF 14A | view · |
| 4 | 2025-09-04 | FORM 4 | view · |
| 8-K | 2025-08-18 | 8-K | view · |
| 8-K | 2025-08-12 | 8-K | view · |
| 10-K | 2025-08-07 | 10-K | view · |
| 8-K | 2025-08-07 | 8-K | view · |
| 8-K | 2025-07-18 | 8-K | view · |
| 4 | 2025-07-17 | FORM 4 | view · |
| 4 | 2025-07-17 | OWNERSHIP DOCUMENT | view · |
| 4 | 2025-07-17 | FORM 4 | view · |
| 4 | 2025-07-17 | FORM 4 | view · |
| 4 | 2025-07-17 | FORM 4 | view · |
| 4 | 2025-07-17 | FORM 4 | view · |
| 4 | 2025-07-17 | FORM 4 | view · |
| 4 | 2025-07-17 | FORM 4 | view · |
| 4 | 2025-07-10 | FORM 4 | view · |
| 4 | 2025-07-10 | FORM 4 | view · |
| 4 | 2025-07-10 | FORM 4 | view · |
| 4 | 2025-05-28 | 4 | view · |
| 4 | 2025-05-22 | FORM 4 | view · |
| 4 | 2025-05-16 | 4 | view · |
| 4 | 2025-05-12 | 4 | view · |
| 4 | 2025-05-07 | 4 | view · |
| 8-K | 2025-04-16 | 8-K | view · |
| 4 | 2025-04-16 | FORM 4 | view · |
| 8-K | 2025-04-10 | 8-K | view · |
| 10-Q | 2025-04-03 | 10-Q | view · |
| 8-K | 2025-04-03 | 8-K | view · |
| DEF 14A | 2025-02-27 | DEF 14A | view · |
| 8-K | 2025-01-17 | 8-K | view · |
| 4 | 2025-01-08 | FORM 4 | view · |
| 8-K | 2025-01-07 | 8-K | view · |
| 10-Q | 2025-01-02 | 10-Q | view · |
| 8-K | 2025-01-02 | 8-K | view · |
| 4 | 2024-12-10 | FORM 4 | view · |
| 4 | 2024-12-10 | FORM 4 | view · |
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is…
Options picks · LFCR
ITM + OTM ideas from the latest scanLoading…
Congress trades · LFCR
STOCK Act disclosuresLoading…
SEC filings & insiders · LFCR
EDGAR · liveLoading…
Holders · LFCR
Institutions & insider activityLoading…